HCG Q2 FY27 Revenue Up 16% YoY to ₹7,318 Mn, Adjusted EBITDA Grows 17% YoY
Healthcare Global Enterprises Limited (HCG) reported Q2 FY27 revenue of ₹7,318 million, up 16% YoY. Adjusted EBITDA grew 17% YoY to ₹1,425 million with improved margins. Patient volumes increased 9% and ARPP by 7%. The company added 25 beds and deployed advanced technologies, including CAR-T cell therapy.
The announcement includes detailed financial results with significant YoY growth, operational improvements, and strategic business developments, which are material to investors.
The company reported strong year-on-year growth in revenue and adjusted EBITDA, along with improvements in operational metrics and strategic business developments.
Healthcare Global Enterprises Limited (HCG) announced its unaudited financial results for the quarter and six months ended September 30, 2026. The company reported a consolidated revenue from operations of ₹7,318 million for Q2 FY27, marking a 15.8% year-on-year increase from ₹6,321 million in Q2 FY26. For the half-year ended September 30, 2026 (H1 FY27), revenue grew by 14.6% YoY to ₹14,100 million from ₹12,303 million in H1 FY26.
Adjusted EBITDA for Q2 FY27 stood at ₹1,425 million, up 17.2% YoY from ₹1,215 million in Q2 FY26. The adjusted EBITDA margin improved by 51 basis points to 19.7% in Q2 FY27. For H1 FY27, Adjusted EBITDA increased by 18.3% YoY to ₹2,740 million, with a margin of 19.7%, up 84 basis points from H1 FY26.
Profit Before Tax (PBT) before extraordinary items saw a significant increase of 48.1% YoY to ₹301 million in Q2 FY27, and by 68.4% YoY to ₹553 million in H1 FY27. Adjusted Profit After Tax (PAT) declined by 9.3% YoY to ₹192 million in Q2 FY27, but grew by 29.2% YoY to ₹358 million in H1 FY27. The decline in Q2 FY27 Adjusted PAT is attributed to a favourable one-time deferred tax adjustment in Q2 FY26.
Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman, highlighted HCG's focus on advancing oncology care through clinical excellence, innovation, and research, with efforts to strengthen capabilities in multi-omics, organoid technology, and cellular therapies. Dr. Manish Mattoo, CEO, commented on the sustained growth momentum, driven by a 9% increase in patient volumes and a 7% improvement in average revenue per patient (ARPP). The company also noted the strategic emphasis on expanding the non-institutional business, which improved its share by 325 basis points YoY to 69%.
Key business developments during the quarter included adding 25 operational beds, deploying advanced technology such as MR-LINAC and robotic surgery systems, and initiating new clinical programs like CAR-T cell therapy and advanced cancer therapies. International business revenue grew by approximately 54% YoY to ₹302 million in Q2 FY27.
What to do with a filing like this
Healthcare Global Enterprises Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Healthcare Global Enterprises Limited. Read the original for the full detail.